Patent Owners Would Get Better Shot At Quashing IPR Petitions Under USPTO Rule
Executive Summary
Proposed rule would eliminate petitioner advantage when patent board is deciding whether to institute inter partes review of patent claims.
You may also be interested in...
Inter Partes Patent Challenges Are Constitutional, US Supreme Court Rules
But Patent Trial and Appeals Board must issue final written decision on all claims raised by challenger – not just some of them, court says; rulings in two closely watched cases mean that IPR proceedings can continue unabated, but generic drug and biosimilar sponsors may need to rethink how they go about challenging innovator patent claims.
PTO Keeps Patent Claim Standard Broad; Spotlight Shifts To Supreme Court
Brand pharma gets a few wins in final rule on Patent Trial and Appeal Board practices, but not the big shift it was seeking.
RSV Vaccine May Be On Market In 2023, CDC’s ACIP Anticipates
Panel expects to review five respiratory syncytial virus vaccines and vote on one or two of them in June 2023 and others four months later. Sanofi presents results of three clinical trials of its monoclonal antibody nirsevimab, which is on track to be the second RSV prophylaxis for infants.